C4 Therapeutics initiated with a Buy at TD Cowen

TD Cowen initiated coverage of C4 Therapeutics (CCCC) with a Buy rating and no price target C4 is one of the few companies with clinical validation across molecular glues and heterobifunctional degraders, the analyst tells investors in a research note. The firm believes the company’s Cemsi could become a “backbone therapy” for myeloma .